Product Description
STAb-T19 is a cellular cancer immunotherapy developed as a treatment for patients with relapsed or refractory CD19-positive B-cell malignancies. It will enter clinical trials in early 2024. (Sourced from: https://stabtherapeutics.com/)
Mechanisms of Action: CAR-T,CD19
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: STAb Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|